Page last updated: 2024-10-26

doxazosin and Body Weight

doxazosin has been researched along with Body Weight in 13 studies

Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension."9.06Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986)
" After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks."6.68[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. ( Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995)
"Essential hypertension is characterized by an insulin-resistance state that may be responsible for the increased atherogenesis typical of this disease."6.67Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. ( Appendino, M; Giorda, C, 1993)
"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values."5.33Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005)
"A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension."5.06Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986)
" After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks."2.68[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. ( Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995)
"Essential hypertension is characterized by an insulin-resistance state that may be responsible for the increased atherogenesis typical of this disease."2.67Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. ( Appendino, M; Giorda, C, 1993)
"Doxazosin treated rats had significantly heavier prostates compared to control rats."1.33Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling. ( Foster, HE; Latifpour, J; Mane, S; Shin, D; Yono, M, 2005)
"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values."1.33Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005)
"Doxazosin treatment prevented the impairment in endothelium-dependent vascular relaxation in the high cholesterol/antioxidant-deficient group."1.30Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. ( Coffee, K; Guerra, J; Hayakawa, H; Raij, L, 1997)
"Doxazosin treatment partially prevented the accumulation of cholesterol and triglycerides in the liver."1.28Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster. ( Birkenhäger, JC; Jansen, H, 1991)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19902 (15.38)18.7374
1990's8 (61.54)18.2507
2000's3 (23.08)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yono, M1
Foster, HE1
Shin, D1
Mane, S1
Latifpour, J1
Shyu, KG1
Liou, JY1
Wang, BW1
Fang, WJ1
Chang, H1
Justulin, LA1
Delella, FK1
Felisbino, SL1
McLeod, SD1
Cairncross, KD1
Tomiyama, H1
Kushiro, T1
Abeta, H1
Ishii, T1
Takahashi, A1
Furukawa, L1
Asagami, T1
Hino, T1
Saito, F1
Otsuka, Y1
Giorda, C1
Appendino, M1
Dines, CD1
Cotter, MA1
Cameron, NE1
Puddu, P1
Gallucci, M1
Curnis, A1
Pupita, F1
Ansuini, R1
Malacco, E1
Raij, L1
Hayakawa, H1
Coffee, K1
Guerra, J1
Jansen, H1
Birkenhäger, JC1
Jansson, JH1
Johansson, B1
Boman, K1
Nilsson, TK1
Ames, RP1
Chrysant, SG1
Gonzalez, F1
Schnaper, HW1
Spann, S1
Velasquez, MT1
Torvik, D1
Madsbu, HP1

Trials

5 trials available for doxazosin and Body Weight

ArticleYear
Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.
    Metabolism: clinical and experimental, 1993, Volume: 42, Issue:11

    Topics: Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Doxazosin; Female; Follow-Up Studies; Gluco

1993
[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension].
    La Clinica terapeutica, 1995, Volume: 146, Issue:12

    Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Body Weight; D

1995
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:4

    Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi

1991
Effectiveness of doxazosin in systemic hypertension.
    The American journal of cardiology, 1989, Jul-15, Volume: 64, Issue:3

    Topics: Adult; Antihypertensive Agents; Body Weight; Double-Blind Method; Doxazosin; Drug Administration Sch

1989
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
    British journal of clinical pharmacology, 1986, Volume: 21 Suppl 1

    Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Do

1986

Other Studies

8 other studies available for doxazosin and Body Weight

ArticleYear
Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling.
    Life sciences, 2005, Jun-10, Volume: 77, Issue:4

    Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals

2005
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
    Journal of biomedical science, 2005, Volume: 12, Issue:2

    Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; C

2005
Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobes.
    Cell and tissue research, 2008, Volume: 332, Issue:1

    Topics: Animals; Apoptosis; Body Weight; Cell Proliferation; Collagen; Doxazosin; Epithelial Cells; In Situ

2008
Preliminary evidence of a synergistic alpha 1- and beta 1-adrenoceptor regulation of rat pineal hydroxyindole-O-methyltransferase.
    General and comparative endocrinology, 1995, Volume: 97, Issue:3

    Topics: Acetylserotonin O-Methyltransferase; Aging; Animals; Body Weight; Circadian Rhythm; Doxazosin; Fencl

1995
Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.
    Hypertension (Dallas, Tex. : 1979), 1994, Volume: 23, Issue:4

    Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gl

1994
Nerve function in galactosaemic rats: effects of evening primrose oil and doxazosin.
    European journal of pharmacology, 1995, Aug-15, Volume: 281, Issue:3

    Topics: Animals; Body Weight; Doxazosin; Fatty Acids, Essential; Galactose; gamma-Linolenic Acid; Hypolipide

1995
Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats.
    American journal of hypertension, 1997, Volume: 10, Issue:11

    Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Doxazosin; Endothelium, Vascular;

1997
Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
    Journal of cardiovascular pharmacology, 1991, Volume: 18, Issue:3

    Topics: Adrenergic alpha-Antagonists; Animals; Body Weight; Cholesterol; Cricetinae; Doxazosin; Hydroxymethy

1991